SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glenmark Pharmaceuticals launches Apremilast in India

25 Oct 2017 Evaluate

Glenmark Pharmaceuticals has launched Apremilast, the first advanced oral systemic treatment for Psoriasis in India. Apremilast, which is a phosphodiesterase 4 (PDE4) inhibitor indicated for the treatment of moderate to severe Psoriasis, will revolutionize the treatment of Psoriasis.

The company has launched Apremilast under the brand name Aprezo. It has received approval from DCGI for Apremilast after conducting clinical trials on the molecule as per the regulatory requirements.

Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).


Glenmark Pharma Share Price

2144.10 -63.15 (-2.86%)
10-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1787.10
Dr. Reddys Lab 1271.75
Cipla 1376.25
Zydus Lifesciences 1097.90
Lupin 2248.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×